Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742 is registered in ClinicalTrials.gov with BioSante Pharmaceuticals as lead sponsor.

NCT NCT00612742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00612742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Lead sponsor
BioSante Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2012
Enrollment
3,656 (actual)
Sites
149

Conditions

As the registry lists them; a condition with its own page is linked.

hypoactive sexual desire disorder